No Data
Shenzhen Salubris Pharmaceuticals (002294.SZ): JK07 obtained positive interim data in the MRCT II phase clinical trials for patients with HFrEF and HFpEF.
On January 20, Galunhui reported that Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that it recently received a notification from its subsidiary, Salubris Biotherapeutics, Inc. in the USA, that JK07 has obtained positive interim data in the MRCT II phase clinical trial for patients with HFrEF (Heart Failure with Reduced Ejection Fraction) and HFpEF (Heart Failure with Preserved Ejection Fraction). The interim analysis of the phase II clinical study of JK07 aims to evaluate JK07 in the low-dose group (0.045.
Huafu Securities: The demand potential in the lipid-lowering drug Industry is enormous, and several Innovative Drugs are about to receive data catalysis.
Multiple cutting-edge targets have welcomed data catalysts, with strong certainty in drug viability, suggesting to focus on domestic companies that are targeting new Innovative Drugs for lipid reduction.
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Market Cap Dropped CN¥1.1b Last Week; Private Companies Bore the Brunt
Shenzhen Salubris Pharmaceuticals (002294.SZ): Some small nucleic acid projects will be in preclinical research next year.
Gelonghui reported on December 13 that Shenzhen Salubris Pharmaceuticals (002294.SZ) recently stated in an investor relations activity that some small nucleic acid projects are in preclinical research, and further R&D progress will be announced in due course.
Shenzhen Salubris Pharmaceuticals (002294.SZ): It is expected that 1 to 2 new products will be launched each year in the future.
On December 13th, Gelonghui reported that Shenzhen Salubris Pharmaceuticals (002294.SZ) stated in a recent investor relations activity that the company is deeply engaged in the chronic disease field, focusing on cardiovascular and cerebrovascular areas, while expanding into nephrology, orthopedics, metabolism, and autoimmune fields. The company currently has 4 newly launched drugs, primarily for hypertension, nephrology, and diabetes, and it is expected that 1-2 new products will be launched each year in the future. With the aging population, the demand in these areas will also be tremendous, and the company's products have distinguishing features, leading to a good outlook.
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Price Is Out Of Tune With Earnings
